Funding Measure

CARB-X

CARB-X is a non-profit public-private partnership with the mission to advance research on antimicrobial resistance globally. The focus lies on innovative research and the development of novel antibacterial agents and therapies designed to counteract the rising burden of antimicrobial resistance. CARB-X currently supports more than 30 projects on early stages of development of antibiotics, other therapeutics, vaccines and diagnostics. In the beginning of 2019 Germany has participated in the CARB-X initiative. With around 40 million euros, the BMBF will continuously support the global partnership for the next 5 years.

Subprojects

CARB-X

Reference number: 01KA1820A-C
Total Funding Amount: 980.581 EUR
Funding Period: 2019 - 2021
Project leader: Dr. Timo Jäger
Address: German Center for Infection Research (DZIF) e.V.
Inhoffenstr. 7
38124 Braunschweig

CARB-X

In addition to the direct funding of CARB-X, the BMBF funds the so-called "CARB-X accelerator" on a national level with around EUR 1 million. The CARB-X accelerator is composed of the product development unit (PDU) of the German Center for Infection Research (DZIF), together with the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute (PEI). They are at the disposal of applicants and projects for scientific-regulatory questions. Further they advise and accompany researchers on their way to a potential CARB-X funding. BfArM and PEI especially support this process with regard to regulatory questions in the context of scientific consulting events as well as in the implementation of trainings. This project combines different phases: the phase of the discovery of new therapeutic approaches, their pharmaceutical and preclinical development, as well as clinical trials.